| abstract |
The present invention relates to novel substituted methylamines, serotonin 5-HT 6 receptor antagonists, active ingredients, pharmaceutical compositions and methods for preventing and treating central nervous system diseases, and molecular tools, wherein The new substituted methylamines have the general formula 1 And a crystalline form, a polycrystalline form, a pharmaceutically acceptable salt and / or a hydrate thereof, wherein W is naphthalene, indolizine or quinoline; R1 is hydrogen, Fluorine, chlorine, methyl; R2 is hydrogen, fluorine, methyl, phenyl, thiophen-2-yl, furan-2-yl, pyridyl, piperazin-1-yl or 4-methylpiperazin-1-yl; R3 is methyl; or W is benzene, R3 has the above meaning; R1 is 3-Cl, R2 is 3-piperazin-1-yl or 3- (4 -Methylpiperazin-1-yl); or R1 is hydrogen; R2 is phenyl or pyridyl; or R1 is hydrogen, fluorine, chlorine, methyl; R2 is 4-piperazine -1-Il or 4- (4-methylpiperazin-1-yl); or W is oxazole and R3 is optionally substituted methyl; R1 is chlorine or fluorine; R2 is Or R1 is hydrogen, fluorine, chlorine, methyl; R2 is piperazin-1-yl, 4-methylpiperazin-1-yl; or R1 is chlorine, fluorine, or methyl R2 is furan-2-yl, or R1 is hydrogen, fluorine, chlorine, methyl; R2 is furan-2-yl, and R3 is (tetrahydrofuran-2-yl) Or R1 is hydrogen, fluorine, chlorine, methyl; R2 is thiophen-2-yl, R3 is 2-methoxyethyl, or R1 is chlorine or fluorine , 2 is a thiophen-2-yl, R3 is methyl. |